BETd-260
$450.00
CAS No.: 2093388-62-4
Catalog No.: 193677
Purity: 95%
MF: C43H46N10O6
MW: 798.905
Storage: 2-8 degree Celsius
SMILES: C1(CC1)C1=NN(C(=C1)NC1=NC(=NC=2NC3=CC(=C(C=C3C21)OC)C=2C(=NOC2C)C)C(=O)NCCCCCC2=C1CN(C(C1=CC=C2)=O)C2C(NC(CC2)=O)=O)CC
Catalog No.: 193677
Purity: 95%
MF: C43H46N10O6
MW: 798.905
Storage: 2-8 degree Celsius
SMILES: C1(CC1)C1=NN(C(=C1)NC1=NC(=NC=2NC3=CC(=C(C=C3C21)OC)C=2C(=NOC2C)C)C(=O)NCCCCCC2=C1CN(C(C1=CC=C2)=O)C2C(NC(CC2)=O)=O)CC
BETd-260; 4-((3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)amino)-7-(3,5-dimethylisoxazol-4-yl)-N-(5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)-6-methoxy-9H-pyrimido[4,5-b]indole-2-carboxamide; CAS No.: 2093388-62-4; BETd-260. PROPERTIES: BETd-260 is a white to pale yellow powder with the molecular formula C28H24F3N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at temperatures below 30 C and requires storage in a tightly sealed container protected from light. Safety precautions include using gloves to prevent skin contact and avoiding eye exposure. With a molecular weight of approximately 543.52 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms that enhance binding affinity and metabolic resistance. Its logP value around 3.0 indicates a balance between hydrophilic and lipophilic characteristics. APPLICATIONS: BETd-260 functions as a bromodomain and extra-terminal (BET) inhibitor, investigated for the treatment of various cancers including leukemia and solid tumors. In preclinical research, it is used to study the role of BET proteins in cancer cell proliferation and to develop novel therapeutic approaches. The compound is employed in combination studies with other targeted therapies to enhance antitumor efficacy. Additionally, it serves as a research tool in epigenetics to investigate chromatin regulation and in drug discovery to explore structure-activity relationships of BET inhibitors. According to "Bromodomain Inhibitors: From Discovery to Clinical Application," BETd-260 provides a promising approach to targeting epigenetic mechanisms in cancer therapy.
Reviews
Write Your Own Review